14 results about "Cysteine protease" patented technology

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The present invention provides a probe compound for labeling a cysteine protease based on activity. The compound targets the protease through a specific targeting element. The compound also includes a detectable element, such as a fluorescent label, a radioactive label, or a chelator. In some cases, the compound also includes a quenching element that is released upon reaction with the protease. The present invention also provides compositions comprising the compound, as well as methods of using the compound, such as labeling a protease in an animal and visualizing a tumor in an animal.

This invention discloses the application of a Trichinella spiralis cysteine ​​protease inhibitor in acute myocardial infarction and subsequent ventricular remodeling, belonging to the field of medicinal chemistry. This invention provides a drug that can prevent, alleviate, and / or treat acute myocardial infarction and subsequent ventricular remodeling. The active ingredient of this drug is the Trichinella spiralis cysteine ​​protease inhibitor cystatin, abbreviated as rTs-Cys. rTs-Cys can effectively delay acute myocardial infarction and inflammatory response in mice, reduce the infarct area, improve cardiac function deterioration, and reverse organ pathological damage, providing a new approach for the clinical treatment of acute myocardial infarction and subsequent ventricular remodeling.

A recombinant TEV protease, a preparation method therefor, and use thereof, relating to the technical field of biology. Specifically provided are four recombinant TEV proteases derived from a cysteine protease of tobacco etch virus. In each of the four recombinant TEV proteases, the N-terminus is fused with an 8His-CL7-GGS tag, and the C-terminus is fused with a polyarginine tag. Compared to a wild-type TEV protease, the provided four recombinant TEV proteases not only can overcome defects such as self-cleavage, poor solubility, and low activity during expression and purification of the wild-type TEV protease, but also have improved protein yield 5-6 times higher than that of the wild-type TEV enzyme, and enzyme activity 10-20 times higher than that of the wild-type TEV protease. In addition, the engineered TEV protease mutants also possess higher thermal stability with a Tm value 10-30 °C higher than that of the wild-type TEV protease, exhibit better protein stability, have broader application conditions, and are more suitable for large-scale production and industrial use.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention discloses a biomimetic catalyst based on an MOF material, a preparation method of the biomimetic catalyst and application of the biomimetic catalyst in peptide synthesis. According to the method, firstly, a novel functional ligand is designed and synthesized, and the ligand integrates nucleophilic sulfydryl, proton transfer imidazolyl and skeleton connection carboxyl and can simulate a'catalytic triad 'of an enzyme active center. Then, the ligand, metal salt and terephthalic acid are co-assembled through a solvothermal method, and the bionic MOF material is prepared. The material has regular nanopore channels and high stability, and can accurately simulate the catalytic mechanism of cysteine protease. The catalyst is used for catalyzing peptide synthesis reaction, amino-acid ester condensation can be efficiently catalyzed to form peptide bonds under the mild and green conditions without chemical coupling agents, the conversion rate is high, the catalyst is easy to recycle, the inherent defects of a traditional chemical synthesis method and an enzyme method are overcome, and a new strategy is provided for green peptide synthesis.

Provided herein are compounds having a structure of formula (I) or formula (II):or a pharmaceutically acceptable salt, solvate, or hydrate thereof, useful in treating or preventing coronavirus infection. In some embodiments, the coronavirus infection is COVID-19 (SARS-COV-19). Also provided are compositions comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus infection.

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

To provide an isolated polypeptide comprising a tandem substrate, an activatable antibody that specifically binds to a target and a production method therefor, and methods for using these in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention provides polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP).SELECTED DRAWING: Figure 1

The present invention relates to anti-coronavirus compounds. The present invention includes a method for preventing and / or treating coronavirus infection by inhibiting cysteine proteases in viruses, in particular SARS-COV-2. Also provided are compositions / pharmaceutical compositions for preventing and / or treating coronavirus infection comprising any of the compounds, pharmaceutically acceptable salts thereof or mixtures thereof, and uses of the compounds.

The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.